Metformin in Postmenopausal Women With Metabolic Syndrome
Launched by MAHIDOL UNIVERSITY · Apr 26, 2011
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Postmenopausal women aged 45-60 years with metabolic syndrome according to The American Heart Association and The National Heart, Lung, and Blood Institute
- Exclusion Criteria:
- • Previous cardiovascular diseases
- • Contraindicated to metformin: serum creatinine \>1.4 mg/dL, liver disease, alcoholism, congestive heart failure, chronic hypoxic lung disease, prior history of lactic acidosis
- • Previous administration of metformin, other hypoglycemic drugs, lipid-lowering drugs, sex steroids, antiplatelet drugs within 3 months before enrollment
- • Fasting blood sugar ≥ 200 mg/dL or HbA1c \>8%
- • Serum triglyceride ≥500 mg/dL
- • Abnormal EKG
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkoknoi, Bangkok, Thailand
Patients applied
Trial Officials
Suchada Indhavivadhana, M.D.
Principal Investigator
Mahidol University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials